Zobrazeno 1 - 10 of 925 pro vyhledávání: '"Harlfinger, S."'
1
Akademický článek
Mechanistic safety assessment via multi-omic characterisation of systemic pathway perturbations following in vivo MAT2A inhibition.
Autor: Fogal V; Oncology Safety, Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK.; Cancer Metabolism & Systems Toxicology Group, Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK., Michopoulos F; Bioscience, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Jarnuczak AF; Data Sciences & Quantitative Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK., Hamza GM; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, R&D Boston, Waltham, USA., Harlfinger S; DMPK, Oncology R&D, AstraZeneca, Cambridge, UK., Davey P; Chemistry, Oncology R&D AstraZeneca, Cambridge, UK., Hulme H; Imaging and Data Analytics, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK., Atkinson SJ; Chemistry, Oncology R&D AstraZeneca, Cambridge, UK., Gabrowski P; Biological Insights Knowledge Graph, R&D IT, AstraZeneca, Barcelona, Spain., Cheung T; Oncology R&D, AstraZeneca, R&D Boston, Waltham, USA., Grondine M; Oncology R&D, AstraZeneca, R&D Boston, Waltham, USA., Hoover C; Oncology Safety Pathology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, R&D Boston, Waltham, USA., Rose J; Animal Science & Technologies, R&D, AstraZeneca, Cambridge, UK., Bray C; Cancer Metabolism & Systems Toxicology Group, Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK., Foster AJ; Regulatory Toxicology and Safety Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK., Askin S; Advanced Drug Delivery, Pharmaceutical Sci, R&D, AstraZeneca, Cambridge, UK., Majumder MM; Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Fitzpatrick P; Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Miele E; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, R&D Boston, Waltham, USA., Macdonald R; Animal Science & Technologies, R&D, AstraZeneca, Cambridge, UK., Keun HC; Cancer Metabolism & Systems Toxicology Group, Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK., Coen M; Oncology Safety, Safety Sciences, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK. muireann.coen@astrazeneca.com.
Publikováno v: Archives of toxicology [Arch Toxicol] 2024 Aug; Vol. 98 (8), pp. 2589-2603. Date of Electronic Publication: 2024 May 17.
Zobrazit plný text záznamu
2
Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
Autor: Chapeau EA; Novartis BioMedical Research, Basel, Switzerland. emilie.chapeau@novartis.com., Sansregret L; Novartis BioMedical Research, Basel, Switzerland., Galli GG; Novartis BioMedical Research, Basel, Switzerland., Chène P; Novartis BioMedical Research, Basel, Switzerland., Wartmann M; Novartis BioMedical Research, Basel, Switzerland., Mourikis TP; Novartis BioMedical Research, Basel, Switzerland., Jaaks P; Novartis BioMedical Research, Basel, Switzerland., Baltschukat S; Novartis BioMedical Research, Basel, Switzerland., Barbosa IAM; Novartis BioMedical Research, Basel, Switzerland., Bauer D; Novartis BioMedical Research, Basel, Switzerland., Brachmann SM; Novartis BioMedical Research, Basel, Switzerland., Delaunay C; Novartis BioMedical Research, Basel, Switzerland., Estadieu C; Novartis BioMedical Research, Basel, Switzerland., Faris JE; Novartis BioMedical Research, Cambridge, MA, USA., Furet P; Novartis BioMedical Research, Basel, Switzerland., Harlfinger S; Novartis BioMedical Research, Basel, Switzerland.; AstraZeneca, Oncology R&D, Cambridge, UK., Hueber A; Novartis BioMedical Research, Basel, Switzerland., Jiménez Núñez E; Novartis BioMedical Research, Basel, Switzerland., Kodack DP; Novartis BioMedical Research, Cambridge, MA, USA., Mandon E; Novartis BioMedical Research, Basel, Switzerland., Martin T; Novartis BioMedical Research, Basel, Switzerland., Mesrouze Y; Novartis BioMedical Research, Basel, Switzerland., Romanet V; Novartis BioMedical Research, Basel, Switzerland., Scheufler C; Novartis BioMedical Research, Basel, Switzerland., Sellner H; Novartis BioMedical Research, Basel, Switzerland., Stamm C; Novartis BioMedical Research, Basel, Switzerland., Sterker D; Novartis BioMedical Research, Basel, Switzerland., Tordella L; Novartis BioMedical Research, Basel, Switzerland., Hofmann F; Novartis BioMedical Research, Basel, Switzerland.; Pierre Fabre Group, R&D Medical Care, Toulouse, France., Soldermann N; Novartis BioMedical Research, Basel, Switzerland., Schmelzle T; Novartis BioMedical Research, Basel, Switzerland. tobias.schmelzle@novartis.com.
Publikováno v: Nature cancer [Nat Cancer] 2024 Jul; Vol. 5 (7), pp. 1130.
Zobrazit plný text záznamu
3
Akademický článek
Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
Autor: Chapeau EA; Novartis BioMedical Research, Basel, Switzerland. emilie.chapeau@novartis.com., Sansregret L; Novartis BioMedical Research, Basel, Switzerland., Galli GG; Novartis BioMedical Research, Basel, Switzerland., Chène P; Novartis BioMedical Research, Basel, Switzerland., Wartmann M; Novartis BioMedical Research, Basel, Switzerland., Mourikis TP; Novartis BioMedical Research, Basel, Switzerland., Jaaks P; Novartis BioMedical Research, Basel, Switzerland., Baltschukat S; Novartis BioMedical Research, Basel, Switzerland., Barbosa IAM; Novartis BioMedical Research, Basel, Switzerland., Bauer D; Novartis BioMedical Research, Basel, Switzerland., Brachmann SM; Novartis BioMedical Research, Basel, Switzerland., Delaunay C; Novartis BioMedical Research, Basel, Switzerland., Estadieu C; Novartis BioMedical Research, Basel, Switzerland., Faris JE; Novartis BioMedical Research, Cambridge, MA, USA., Furet P; Novartis BioMedical Research, Basel, Switzerland., Harlfinger S; Novartis BioMedical Research, Basel, Switzerland.; AstraZeneca, Oncology R&D, Cambridge, UK., Hueber A; Novartis BioMedical Research, Basel, Switzerland., Jiménez Núñez E; Novartis BioMedical Research, Basel, Switzerland., Kodack DP; Novartis BioMedical Research, Cambridge, MA, USA., Mandon E; Novartis BioMedical Research, Basel, Switzerland., Martin T; Novartis BioMedical Research, Basel, Switzerland., Mesrouze Y; Novartis BioMedical Research, Basel, Switzerland., Romanet V; Novartis BioMedical Research, Basel, Switzerland., Scheufler C; Novartis BioMedical Research, Basel, Switzerland., Sellner H; Novartis BioMedical Research, Basel, Switzerland., Stamm C; Novartis BioMedical Research, Basel, Switzerland., Sterker D; Novartis BioMedical Research, Basel, Switzerland., Tordella L; Novartis BioMedical Research, Basel, Switzerland., Hofmann F; Novartis BioMedical Research, Basel, Switzerland.; Pierre Fabre Group, R&D Medical Care, Toulouse, France., Soldermann N; Novartis BioMedical Research, Basel, Switzerland., Schmelzle T; Novartis BioMedical Research, Basel, Switzerland. tobias.schmelzle@novartis.com.
Publikováno v: Nature cancer [Nat Cancer] 2024 Jul; Vol. 5 (7), pp. 1102-1120. Date of Electronic Publication: 2024 Apr 02.
Zobrazit plný text záznamu
4
Akademický článek
Utilizing a Dual Human Transporter MDCKII-MDR1-BCRP Cell Line to Assess Efflux at the Blood Brain Barrier.
Autor: Colclough N; DMPK, Oncology R & D, AstraZeneca, Cambridge, United Kingdom (N.C., J.W.T., E.G., S.H., D.F.M.); Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.V.A.); DMPK, Pharmaron, Beijing, China (D.L., H.D., W.L.); Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (D.J.O., G.G.S.); and DMPK Asia, Oncology R & D, AstraZeneca, Shanghai, China (K.C., Y.Y.) Nicola.Colclough@astrazeneca.com., Alluri RV; DMPK, Oncology R & D, AstraZeneca, Cambridge, United Kingdom (N.C., J.W.T., E.G., S.H., D.F.M.); Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.V.A.); DMPK, Pharmaron, Beijing, China (D.L., H.D., W.L.); Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (D.J.O., G.G.S.); and DMPK Asia, Oncology R & D, AstraZeneca, Shanghai, China (K.C., Y.Y.)., Tucker JW; DMPK, Oncology R & D, AstraZeneca, Cambridge, United Kingdom (N.C., J.W.T., E.G., S.H., D.F.M.); Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.V.A.); DMPK, Pharmaron, Beijing, China (D.L., H.D., W.L.); Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (D.J.O., G.G.S.); and DMPK Asia, Oncology R & D, AstraZeneca, Shanghai, China (K.C., Y.Y.)., Gozalpour E; DMPK, Oncology R & D, AstraZeneca, Cambridge, United Kingdom (N.C., J.W.T., E.G., S.H., D.F.M.); Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.V.A.); DMPK, Pharmaron, Beijing, China (D.L., H.D., W.L.); Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (D.J.O., G.G.S.); and DMPK Asia, Oncology R & D, AstraZeneca, Shanghai, China (K.C., Y.Y.)., Li D; DMPK, Oncology R & D, AstraZeneca, Cambridge, United Kingdom (N.C., J.W.T., E.G., S.H., D.F.M.); Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.V.A.); DMPK, Pharmaron, Beijing, China (D.L., H.D., W.L.); Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (D.J.O., G.G.S.); and DMPK Asia, Oncology R & D, AstraZeneca, Shanghai, China (K.C., Y.Y.)., Du H; DMPK, Oncology R & D, AstraZeneca, Cambridge, United Kingdom (N.C., J.W.T., E.G., S.H., D.F.M.); Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.V.A.); DMPK, Pharmaron, Beijing, China (D.L., H.D., W.L.); Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (D.J.O., G.G.S.); and DMPK Asia, Oncology R & D, AstraZeneca, Shanghai, China (K.C., Y.Y.)., Li W; DMPK, Oncology R & D, AstraZeneca, Cambridge, United Kingdom (N.C., J.W.T., E.G., S.H., D.F.M.); Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.V.A.); DMPK, Pharmaron, Beijing, China (D.L., H.D., W.L.); Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (D.J.O., G.G.S.); and DMPK Asia, Oncology R & D, AstraZeneca, Shanghai, China (K.C., Y.Y.)., Harlfinger S; DMPK, Oncology R & D, AstraZeneca, Cambridge, United Kingdom (N.C., J.W.T., E.G., S.H., D.F.M.); Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.V.A.); DMPK, Pharmaron, Beijing, China (D.L., H.D., W.L.); Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (D.J.O., G.G.S.); and DMPK Asia, Oncology R & D, AstraZeneca, Shanghai, China (K.C., Y.Y.)., O'Neill DJ; DMPK, Oncology R & D, AstraZeneca, Cambridge, United Kingdom (N.C., J.W.T., E.G., S.H., D.F.M.); Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.V.A.); DMPK, Pharmaron, Beijing, China (D.L., H.D., W.L.); Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (D.J.O., G.G.S.); and DMPK Asia, Oncology R & D, AstraZeneca, Shanghai, China (K.C., Y.Y.)., Sproat GG; DMPK, Oncology R & D, AstraZeneca, Cambridge, United Kingdom (N.C., J.W.T., E.G., S.H., D.F.M.); Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.V.A.); DMPK, Pharmaron, Beijing, China (D.L., H.D., W.L.); Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (D.J.O., G.G.S.); and DMPK Asia, Oncology R & D, AstraZeneca, Shanghai, China (K.C., Y.Y.)., Chen K; DMPK, Oncology R & D, AstraZeneca, Cambridge, United Kingdom (N.C., J.W.T., E.G., S.H., D.F.M.); Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.V.A.); DMPK, Pharmaron, Beijing, China (D.L., H.D., W.L.); Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (D.J.O., G.G.S.); and DMPK Asia, Oncology R & D, AstraZeneca, Shanghai, China (K.C., Y.Y.)., Yan Y; DMPK, Oncology R & D, AstraZeneca, Cambridge, United Kingdom (N.C., J.W.T., E.G., S.H., D.F.M.); Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.V.A.); DMPK, Pharmaron, Beijing, China (D.L., H.D., W.L.); Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (D.J.O., G.G.S.); and DMPK Asia, Oncology R & D, AstraZeneca, Shanghai, China (K.C., Y.Y.)., McGinnity DF; DMPK, Oncology R & D, AstraZeneca, Cambridge, United Kingdom (N.C., J.W.T., E.G., S.H., D.F.M.); Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (R.V.A.); DMPK, Pharmaron, Beijing, China (D.L., H.D., W.L.); Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom (D.J.O., G.G.S.); and DMPK Asia, Oncology R & D, AstraZeneca, Shanghai, China (K.C., Y.Y.).
Publikováno v: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Jan 09; Vol. 52 (2), pp. 95-105. Date of Electronic Publication: 2024 Jan 09.
Zobrazit plný text záznamu
5
Akademický článek
Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRAS G12C with Demonstrable CNS Penetration.
Autor: Kettle JG; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Bagal SK; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Barratt D; Discovery Sciences, R&D, AstraZeneca,, Cambridge CB4 0WG, U.K., Bodnarchuk MS; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Boyd S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Braybrooke E; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Breed J; Discovery Sciences, R&D, AstraZeneca,, Cambridge CB4 0WG, U.K., Cassar DJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Cosulich S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Davies M; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Davies NL; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Deng C; Pharmaron Beijing Co., Ltd. 6 Taihe Road BDA, Beijing 100176, P. R. China., Eatherton A; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Evans L; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Feron LJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Fillery S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Gleave ES; Discovery Sciences, R&D, AstraZeneca,, Cambridge CB4 0WG, U.K., Goldberg FW; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Cortés González MA; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm SE-171 76, Sweden., Guerot C; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Haider A; Discovery Sciences, R&D, AstraZeneca,, Cambridge CB4 0WG, U.K., Harlfinger S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Howells R; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Jackson A; Discovery Sciences, R&D, AstraZeneca,, Cambridge CB4 0WG, U.K., Johnström P; PET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Karolinska Institutet, Stockholm SE-171 76, Sweden.; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm SE-171 76, Sweden., Kemmitt PD; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Koers A; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Kondrashov M; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm SE-171 76, Sweden., Lamont GM; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Lamont S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Lewis HJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Liu L; Pharmaron Beijing Co., Ltd. 6 Taihe Road BDA, Beijing 100176, P. R. China., Mylrea M; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Nash S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Niedbala MJ; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Peter A; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Phillips C; Discovery Sciences, R&D, AstraZeneca,, Cambridge CB4 0WG, U.K., Pike K; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Raubo P; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Robb GR; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Ross S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Sanders MG; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Schou M; PET Science Centre, Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Karolinska Institutet, Stockholm SE-171 76, Sweden.; Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm SE-171 76, Sweden., Simpson I; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Steward O; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2023 Jul 13; Vol. 66 (13), pp. 9147-9160. Date of Electronic Publication: 2023 Jul 03.
Zobrazit plný text záznamu
6
Akademický článek
The Disconnect in Intrinsic Clearance Determined in Human Hepatocytes and Liver Microsomes Results from Divergent Cytochrome P450 Activities.
Autor: Bapiro TE; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Cambridge, United Kingdom (T.E.B., S.M., S.D.W., A.L.O., S.H., D.F.M.) and Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Boston, Massachusetts (N.H.) tashinga.bapiro1@astrazeneca.com dermot.f.mcginnity@astrazeneca.com., Martin S; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Cambridge, United Kingdom (T.E.B., S.M., S.D.W., A.L.O., S.H., D.F.M.) and Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Boston, Massachusetts (N.H.)., Wilkinson SD; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Cambridge, United Kingdom (T.E.B., S.M., S.D.W., A.L.O., S.H., D.F.M.) and Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Boston, Massachusetts (N.H.)., Orton AL; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Cambridge, United Kingdom (T.E.B., S.M., S.D.W., A.L.O., S.H., D.F.M.) and Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Boston, Massachusetts (N.H.)., Hariparsad N; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Cambridge, United Kingdom (T.E.B., S.M., S.D.W., A.L.O., S.H., D.F.M.) and Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Boston, Massachusetts (N.H.)., Harlfinger S; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Cambridge, United Kingdom (T.E.B., S.M., S.D.W., A.L.O., S.H., D.F.M.) and Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Boston, Massachusetts (N.H.)., McGinnity DF; Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Cambridge, United Kingdom (T.E.B., S.M., S.D.W., A.L.O., S.H., D.F.M.) and Drug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Boston, Massachusetts (N.H.).
Publikováno v: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2023 Jul; Vol. 51 (7), pp. 892-901. Date of Electronic Publication: 2023 Apr 11.
Zobrazit plný text záznamu
7
Akademický článek
Optimization of a Class of Dihydrobenzofurane Analogs toward Orally Efficacious YAP-TEAD Protein-Protein Interaction Inhibitors.
Autor: Sellner H; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland., Chapeau E; Oncology Drug Discovery, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland., Furet P; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland., Voegtle M; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland., Salem B; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland., Le Douget M; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland., Bordas V; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland., Groell JM; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland., Le Goff AL; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland., Rouzet C; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland., Wietlisbach T; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland., Zimmermann T; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland., McKenna J; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland., Brocklehurst CE; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland., Chène P; Oncology Drug Discovery, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland., Wartmann M; Oncology Drug Discovery, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland., Scheufler C; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland., Kallen J; Chemical Biology & Therapeutics, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland., Williams G; Pharmacokinetics Sciences, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland., Harlfinger S; Pharmacokinetics Sciences, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland., Traebert M; Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland., Dumotier BM; Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland., Schmelzle T; Oncology Drug Discovery, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland., Soldermann N; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Basel, 4002, Switzerland.
Publikováno v: ChemMedChem [ChemMedChem] 2023 Jun 01; Vol. 18 (11), pp. e202300051. Date of Electronic Publication: 2023 Apr 13.
Zobrazit plný text záznamu
9
Akademický článek
ADME and DMPK considerations for the discovery and development of antibody drug conjugates (ADCs).
Autor: Beaumont K; Drug Metabolism and Pharmacokinetics, Early Oncology Research and Development, Cambridge, UK., Pike A; Drug Metabolism and Pharmacokinetics, Early Oncology Research and Development, Cambridge, UK., Davies M; Drug Metabolism and Pharmacokinetics, Early Oncology Research and Development, Cambridge, UK., Savoca A; Drug Metabolism and Pharmacokinetics, Early Oncology Research and Development, Cambridge, UK., Vasalou C; Drug Metabolism and Pharmacokinetics, Early Oncology Research and Development, AstraZeneca, Boston, MA, USA., Harlfinger S; Drug Metabolism and Pharmacokinetics, Early Oncology Research and Development, Cambridge, UK., Ramsden D; Drug Metabolism and Pharmacokinetics, Early Oncology Research and Development, AstraZeneca, Boston, MA, USA., Ferguson D; Drug Metabolism and Pharmacokinetics, Early Oncology Research and Development, AstraZeneca, Boston, MA, USA., Hariparsad N; Drug Metabolism and Pharmacokinetics, Early Oncology Research and Development, AstraZeneca, Boston, MA, USA., Jones O; Drug Metabolism and Pharmacokinetics, Early Oncology Research and Development, Cambridge, UK., McGinnity D; Drug Metabolism and Pharmacokinetics, Early Oncology Research and Development, Cambridge, UK.
Publikováno v: Xenobiotica; the fate of foreign compounds in biological systems [Xenobiotica] 2022 Aug; Vol. 52 (8), pp. 770-785.
Zobrazit plný text záznamu
10
Akademický článek
Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRAS G12C .
Autor: Kettle JG; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Bagal SK; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Bickerton S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Bodnarchuk MS; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Boyd S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Breed J; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Carbajo RJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Cassar DJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Chakraborty A; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Cosulich S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Cumming I; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Davies M; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Davies NL; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Eatherton A; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Evans L; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Feron L; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Fillery S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Gleave ES; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Goldberg FW; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Hanson L; Oncology R&D, AstraZeneca, Alderley Park SK10 4TG, U.K., Harlfinger S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Howard M; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Howells R; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Jackson A; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Kemmitt P; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Lamont G; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Lamont S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Lewis HJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Liu L; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China., Niedbala MJ; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Phillips C; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Polanski R; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Raubo P; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Robb G; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Robinson DM; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Ross S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Sanders MG; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Tonge M; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Whiteley R; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Wilkinson S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Yang J; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China., Zhang W; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2022 May 12; Vol. 65 (9), pp. 6940-6952. Date of Electronic Publication: 2022 Apr 26.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje